PYC Therapeutics (ASX:PYC) Accounts Payable: A$9.56 Mil (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
36 GF Score
Price A$1.54
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Accounts Payable?

PYC Therapeutics ASX:PYC -4.95% 36 Accounts Payable is A$9.56 Mil as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

PYC Therapeutics's Accounts Payable for the quarter that ended in Dec. 2025 was A$9.56 Mil.

PYC Therapeutics's quarterly Accounts Payable declined from Dec. 2024 (A$9.92 Mil) to Jun. 2025 (A$8.75 Mil) but then increased from Jun. 2025 (A$8.75 Mil) to Dec. 2025 (A$9.56 Mil).

PYC Therapeutics's annual Accounts Payable increased from Jun. 2023 (A$4.92 Mil) to Jun. 2024 (A$7.53 Mil) and increased from Jun. 2024 (A$7.53 Mil) to Jun. 2025 (A$8.75 Mil).

PYC Therapeutics Accounts Payable Related Terms

PYC Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics Accounts Payable Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.35 2.57 4.92 7.53 8.75

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.41 7.53 9.92 8.75 9.56
ASX:PYC
36GF Score
PYC Therapeutics Ltd ASX:PYC
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$9.56 Mil mean?
PYC Therapeutics (ASX:PYC) has a Accounts Payable of A$9.56 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' Accounts Payable too high?
PYC Therapeutics' current Accounts Payable is A$9.56 Mil. Overall, PYC Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Accounts Payable compare to VRTX and REGN?
PYC Therapeutics' Accounts Payable of A$9.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current Accounts Payable is A$9.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Accounts Payable of A$9.56 Mil. The current Accounts Payable is A$9.56 Mil. PYC Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Accounts Payable is A$9.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
36GF Score

Get the complete analysis for ASX:PYC

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.54
Price